



Bayer AG
Communications
51368 Leverkusen
Germany
Phone +49 214 30-1
www.bayer.com/en/media

News Release

Not intended for U.S. and UK Media

Bayer invests 130 million EUR in new production facility for innovative parenteral products

- Investment part of billion-dollar investment program
 - Commitment to Berlin as an innovation hub
 - Governing Mayor of Berlin, Kai Wegner, inaugurates new facility together with Bayer Board Member Stefan Oelrich
 - New facility equipped with state-of-the-art technology, including a robot-controlled, aseptic filling system for efficient and sterile processes
 - Intelligent combination of new technologies enables faster translation of medication from concept to market, benefiting patients
-

Berlin, November 23, 2023 – Bayer has added a brand new manufacturing facility to its global supply chain network. The new production plant was inaugurated today at the company's global pharmaceutical headquarters in Berlin, Germany. The facility features state-of-the-art technology, innovative production, and automated processes. The inauguration of the facility represents a key milestone in realizing Bayer's global manufacturing strategy for pharmaceutical liquid dosage forms, such as injection and infusion solutions.

"It is of crucial importance that Germany and Europe pursue a clear strategy of a future-oriented innovation policy. Bayer is investing here in research and production to secure future business while strengthening the innovative power in the region," said Stefan Oelrich, Member of the Board of Bayer AG and Head of its Pharmaceuticals Division

The project is part of a billion-dollar investment program through which Bayer AG strengthens its global pharmaceutical production network and its own innovative capabilities.

“It is great to see a German company like Bayer AG driving innovation in Berlin. This investment not only demonstrates loyalty to the location but also strengthens our city as a renowned health metropolis. It sends a clear signal from the economic and healthcare hub of Berlin. With the commissioning of the new pharmaceutical production facility, the commitment to advanced technologies and medical research is further expanded. The successful development of the healthcare industry creates more jobs and benefits our metropolitan region as a whole,” said Kai Wegner, the Governing Mayor of Berlin.

Bayer's new production facility is based on an innovative platform technology that covers a wide range of chemically and biologically based parenteral products. The highly digitized manufacturing process enables safe, fast, and sterile formulation, filling, and freeze-drying of pharmaceuticals. The highly automated robot-based filling machine combines efficient and reliable production of medications, aiming to bring them from concept to market and ultimately to the patients even faster. The facility serves critical manufacturing areas with high medical demand, such as products in the field of ophthalmology. It is intended to supply markets in the USA, Europe, and China in the future.

“The new facility is a significant milestone for our production network. It ensures that high-quality drug forms are available in sufficient quantities, that supply chains become more reliable and efficient and that patients around the world have greater security of supply,” said Holger Weintritt, Member of the Executive Committee Pharmaceuticals and Head of Product Supply at the Pharmaceuticals Division of Bayer AG. “The innovative design of the production enables maximum flexibility for the formulation and filling of aseptic products.”

The facility is located in Germany at Bayer's global pharmaceutical headquarters in Berlin, which is a key global production site for the company and is evolving into a global “Center of Excellence for Parenterals”. The Berlin production site plays a crucial role in the manufacturing and packaging of liquid and solid pharmaceuticals to ensure global market supply.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging

global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Note:

Photos of the event will be made available later in the afternoon at www.bayer.com/media.

Contact for media inquiries:

Simone Kannapinn, Tel.: +49 175 3092113

E-Mail: simone.kannapinn@bayer.com

Joline Günther, Tel.: +49 173 4676240

E-Mail: joline.guenther@bayer.com

Find more information at <https://pharma.bayer.com/>

Follow us on Facebook: <http://www.facebook.com/bayer>

Follow us on Twitter: [@BayerPharma](https://twitter.com/BayerPharma)

jg (2023-0211E)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.